The idea of stopping type 1 diabetes before it even starts is closer to reality than many might think. SAB Bio’s new therapy, SAB-142, is an innovative approach designed to potentially prevent or delay the onset of type 1 diabetes. Unlike traditional thymoglobulin, which is derived from rabbits and can lead to side effects like serum sickness, SAB-142 uses a fully human version produced by genetically engineered cows. This could make the therapy safer and more tolerable for patients.

In my conversation with Sam Reich, CEO of SAB Bio, and Dr. Mike Haller, a leading T1D researcher, we explored how SAB-142 builds on the research behind Teplizumab, a therapy that has shown promise in delaying the onset of Stage 3 type 1 diabetes. SAB-142’s approach focuses on modulating the immune system in the early stages of the disease, potentially altering its course before insulin dependence occurs. The therapy is being studied in clinical trials, with early results showing encouraging signs of safety and effectiveness.

We also talked about the critical role of NIH funding in advancing this type of research. Developing therapies that could prevent type 1 diabetes requires not just innovation, but significant investment in science and clinical studies. SAB Bio’s mission highlights how collaboration between researchers, biotech companies, and funding organizations can accelerate progress in diabetes prevention.

For anyone curious about the future of type 1 diabetes prevention, SAB-142 represents a major step forward. From its human-derived design to its clinical potential, this therapy could change how we approach T1D before it starts.

Watch the full video here to see the discussion with Sam Reich and Dr. Mike Haller in action in the YouTube episode below or listen to the podcast above for a deeper dive. And for more info on research for a cure, listen to our conversation with CEO of Breakthrough T1D, Aaron Kowalski.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.